BioLineRx Beats GAAP EPS Expectations, Misses Revenue Target in Q4

BioLineRx reported FY GAAP EPS of $0.00, beating estimates by $0.68. However, revenue fell to $1.18M, a 95.9% YoY decline and missed expectations by $0.3M. The company maintains a cash runway into the first half of 2027 with $20.9 million on its balance sheet as of December 31, 2025.